Blockage of TIM-3 relieves lupus nephritis by expanding Treg cells and promoting their suppressive capacity in MRL/lpr mice.

T Cell Immunoglobulin and Mucin Containing Protein-3 (TIM-3) is an important immune checkpoint protein that is expressed in Tregs and affects their function. However, the expression and role of TIM-3 in modulating regulatory T cells (Tregs) in lupus nephritis (LN) are still unknown. In this study, we found that the percentage of TIM-3+ cells among spleen lymphocytes, CD4+ T cells and Tregs was higher in MRL/lpr mice than in MpJ mice. TIM-3high CD4+ T cells and TIM-3high Tregs were mainly responsible for the increase. The percentage of Tregs in TIM-3high CD4+ T cells was lower than that in TIM-3low CD4+ T cells, and the expression of CTLA-4 and IL-10 was lower in TIM-3high Tregs than in the TIM-3low Tregs in MRL/lpr mice. Blockade of TIM-3 in vivo significantly increased the Treg population and the expression of CTLA-4 and IL-10 in Tregs, thus relieving the LN symptoms and pathology in MRL/lpr mice. Additionally, bioinformatics analysis indicated that TIM-3 regulates Treg cells in LN mainly through cytokine-cytokine receptor interactions, the PI3K-Akt signaling pathway, the T cell receptor signaling pathway, Th17 cell differentiation and the FoxO signaling pathway. Together, our study has demonstrated that TIM-3 regulates Tregs in LN and that overexpression of TIM-3 in CD4+ T cells and Tregs leads to Treg quantity and quality deficiency in MRL/lpr mice. Blockade of TIM-3 protects against LN by expanding Tregs and enhancing their suppressive capacity. Finally, TIM-3 might be a potential therapeutic target for the treatment of LN.

Bone marrow inhibition induced by azathioprine in a patient without mutation in the thiopurine S-methyltransferase pathogenic site: A case report.

BACKGROUND: Azathioprine (AZA) and its close analog 6-mercaptopurine are thiopurines widely used in the treatment of patients with cancer, organ transplantation, and autoimmune or inflammatory diseases, including systemic lupus erythematosus. Bone marrow inhibition is a common side effect of AZA, and severe bone marrow inhibition is related to decreased thiopurine S-methyltransferase (TPMT) activity. CASE SUMMARY: We herein report a patient with proliferative lupus nephritis who was using AZA for maintenance therapy, had no common TPMT pathogenic site mutations, and exhibited severe bone marrow inhibition on the 15th day after oral administration. CONCLUSION: This report alerts physicians to the fact that even though the TPMT gene has no common pathogenic site mutation, severe myelosuppression may also occur.

Room-temperature synthesis of amino-functionalized magnetic covalent organic frameworks for efficient extraction of perfluoroalkyl acids in environmental water samples.

The novel amino-functionalized magnetic covalent organic framework nanocomposites (Fe3O4@[NH2]-COFs) were fabricated at room temperature, which were explored as a magnetic adsorbent for magnetic solid-phase extraction (MSPE). On the basis of the hydrophobic surfaces of magnetic nanocomposites and introduction of primary amines into the COFs shell, Fe3O4@[NH2]-COFs displayed excellent enrichment capacity in "catching" ultratrace perfluoroalkyl acids (PFAAs) from water samples because of the synergistic combination of hydrophobic and electrostatic interactions between PFAAs and Fe3O4@[NH2]-COFs. Under the optimized pretreatment and instrumental parameters, the proposed pretreatment approach, which hybridized MSPE using Fe3O4@[NH2]-COFs and HPLC-MS/MS, displayed favorable linearity (10-10,000 ng L-1) with R2 (0.9990-0.9999), low limits of detection (0.05-0.38 ng L-1), and excellent repeatability (3.7-9.2%). Moreover, the established approach was successfully utilized to determine PFAAs in real water samples with spiked recoveries ranging from 72.1% to 115.4%. Results indicated that Fe3O4@[NH2]-COFs would be a potential alternative for MSPE of PFAAs at ultra-low levels.